WASHINGTON (AP) — A Washington-based nonprofit is asking a judge to force the Trump administration to stop work on the Lincoln Memorial Reflecting Pool and restore historic elements at one of the most iconic spots on the National Mall.

In a lawsuit filed Monday, The Cultural Landscape Foundation said the administration’s moves to repaint the bottom of the Reflecting Pool blue without undergoing relevant reviews ran afoul to federal preservation laws governing historic sites. The group argued that the changes at the Reflecting Pool are part of President Donald Trump’s broader effort to push through dramatic renovations in Washington without proper reviews and undermine the tone of the area.

“The design intent, to create a reflective surface that is subordinate, is fundamental to the solemn and hallowed visual and spatial connection between the Washington Monument and the Lincoln Memorial,” said Charles A. Birnbaum, the group’s president and CEO, said in a statement. “A blue-tinted basin is more appropriate to a resort or theme park.”

Trump has taken a personal interest in the project, calling the area “filthy” before workers repainted the Reflecting Pool a color he has called “American flag blue.” His motorcade was driven over a drained and repainted Reflecting Pool last week to give him a chance for a firsthand review of the project.

Speaking at a Rose Garden event Monday evening, Trump said the pool would be reopened “sometime next week, week after.” He did not mention the lawsuit in his remarks but said the end result would be beautiful and rebuffed criticism that it was just a new paint job. “This is not paint,” he said. “This is highly sophisticated stuff.”

The suit was filed against the Interior Department and the National Park Service, which oversee much of the renovations underway in Washington. Katie Martin, an Interior Department spokeswoman, said in a statement that Trump “has done more to make our nation’s capital a shining beacon than any other president in the history of this country.”

“The Department is proud of the work being carried out by our Park Service to ensure this magical spot can be enjoyed for not only our 250th, but for many generations to come,” she said.

Over the past year, Trump has bulldozed the East Wing to make way for a ballroom. His name was added to the facades of the U.S. Institute of Peace and the Kennedy Centerwhich he plans to close for a two-year renovation. His face adorns a banner at the Department of Justice’s headquarters, among others. He is pushing for a triumphal arch near Arlington Cemetery and has closed parks, including Lafayette Square across from the White House, for a rehab.

Many of those projects are also subject to litigation.

WASHINGTON (AP) — President Donald Trump’s plan to put weapons in space — pitched as a “Golden Dome for America” missile defense program — is estimated to cost $1.2 trillion over a 20-year period, according to a new analysis from the Congressional Budget Office, a far heftier sum than the initial $175 billion price tag he gave last year.

The nonpartisan CBO report, published Tuesday, is described as an analysis that reflects “one illustrative approach rather than an estimate of a specific Administration proposal.”

The futuristic system was ordered by Trump in an executive order during his first week in office. He said then that he expected the system to be “fully operational before the end of my term,” which wraps up in January 2029.

“Over the past 40 years, rather than lessening, the threat from next-generation strategic weapons has become more intense and complex with the development by peer and near-peer adversaries of next-generation delivery systems,” Trump said in his executive order, justifying the need for the missile defense system.

The CBO’s estimates are in part based on a lack of details from the Defense Department about what and how many systems will be deployed, “making it impossible to estimate the long term cost” of the Golden Dome system, the report says.

The concept for the missile system is at least partly inspired by Israel’s multitiered defenses, often collectively referred to as the “Iron Dome,” which played a key role in defending it from rocket and missile fire from Iran and allied militant groups as it prosecutes the war on Iran alongside the U.S.

The U.S. Golden Dome is envisioned to include ground- and space-based capabilities able to detect, intercept and stop missiles at all major stages of a potential attack.

Congress has already approved roughly $24 billion for the missile defense initiative through Republicans’ massive tax and spending measure signed into law last summer.

Gen. Michael A. Guetlein, director of the Golden Dome project, testified last month about its costs. He told lawmakers that various groups estimating costs “just take the cost of a legacy system and they multiply it out and they get these really large numbers and they say, well, that must be it.

“That is not what Golden Dome is doing,” the U.S. Space Force general said. “We are laser focused on affordability.”

Sen. Jeff Merkley, D-Ore., who requested the estimate from the CBO, said in response to the report that the missile defense project is “nothing more than a massive giveaway to defense contractors paid for entirely by working Americans.”

Last May, the president said the Golden Dome would cost $175 billion. The CBO last year estimated that just the space-based components of the Golden Dome could cost as much as $542 billion over the next 20 years.

WASHINGTON (AP) — The head of the Food and Drug Administration, Dr. Marty Macaryis resigning after a rocky tenure that drew months of complaints from health industry executives, anti-abortion activistsvaping lobbyists and other allies of President Donald Trump.

News of Makary’s departure Tuesday came just 13 months after he was confirmed to lead the powerful regulatory agency.

A surgeon and health researcher, Makary came to prominence among Republicans as an outspoken critic of public health measures during the COVID-19 pandemic, when he frequently appeared on Fox News Channel. But he struggled to manage the FDA’s bureaucracy and failed to win the confidence of its staff after mass layoffsleadership upheavals and a series of controversies in which the agency’s scientific principles appeared to be overridden by political interests, including those of Health Secretary Robert F. Kennedy Jr.

“He’s a great doctor, and he was having some difficulty,” Trump told reporters outside the White House. “But he’s going to go on and he’s going to do well.”

Trump later confirmed in a social media post that Kyle Diamantas, the agency’s chief for foodsis expected to take over as acting commissioner. Diamantas is an attorney with personal ties to Donald Trump Jr.

In that post, the president included what appeared to be a text message from Makary submitting his resignation. In it, he noted: “I announced 50 major FDA reforms. Joe Biden’s FDA had none.” He thanked Trump for the chance to serve.

The FDA commissioner, as the leader of an agency that regulates billions of dollars in consumer goods and medicines, is often required to juggle competing priorities that straddle science and politics.

Makary faced a unique challenge in balancing calls by Trump and other Republicans to cut red tape at the FDA, while also tending to Kennedy’s interest in scrutinizing the safety of vaccinesdrugs and food additives. The decision to get rid of Makary was made by Kennedy, and then the White House signed off on it, according to an administration official who was granted anonymity because they were not authorized to describe internal dynamics.

Virtually all of the FDA’s senior career officials resigned, retired or were forced out in the first year of the second-term Trump administration, leading to a steady stream of leaks and negative stories in the media cataloging low morale, dysfunction and frustration among staff.

Makary’s handpicked deputy, Dr. Vinay Prasadwas pushed out of the agency twice in less than a year for running afoul of specialty drugmakers and groups for patients with rare diseases. Makary appeared poised to weather the controversy, despite an ongoing pressure campaign calling on Trump to fire him.

Recent weeks brought fresh criticisms from other interest groups that the White House considers key to Republican chances in November elections.

Anti-abortion groups have accused Makary of slow-walking an internal review of the abortion pill mifepristonewhich has been on the market for 25 years but remains a target for conservative activists. They are seeking to roll back FDA rules that currently allow the pill to be sent through the mail.

“We look forward to a new FDA commissioner who will put an end to the mail-order abortion drug regime,” said Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America.

Vaping executives told Trump that Makary was blocking approval of their products, including new flavored e-cigarettes seen as crucial to the industry’s survival.

Last week, the agency abruptly changed course, authorizing the first fruit-flavored e-cigarettes and issuing guidelines that loosened marketing for major manufacturers. But it wasn’t enough to keep Makary in the job.

A permanent replacement for the FDA job will need to be nominated by Trump and confirmed by the Senate.

Faster drug reviews are overshadowed

As a former regular on Fox News, Makary was aggressive about promoting his accomplishments on cable television and podcasts and in online opinion pieces.

A string of initiatives from Makary aimed to speed up or streamline FDA drug reviews, including dropping certain study requirementsincorporating artificial intelligence into drug evaluations and offering expedited reviews to medicines that support “national interests.”

But pharmaceutical executives rely on the predictability and consistency of FDA decisions, even more than speedy reviews. Makary’s efforts on drug reviews were overshadowed by internal conflicts and disputes that created headaches for drugmakers, investors and patients.

More than a half-dozen drugmakers studying therapies for rare or hard-to-treat diseases said they received rejection letters or requests to run additional studies for drugs that had previously been given the go-ahead by FDA staff. Those drugs were primarily overseen by Prasad, who stepped down for a second time from his role as the FDA’s vaccine and biotech chief in April.

Vaccine moves denounced

Prasad repeatedly overruled vaccine staffers to restrict eligibility for new coronavirus shots. In February, Prasad initially refused to even consider Moderna’s mRNA shot for flu. The FDA was forced to reverse itself after Moderna pledged to formally challenge the decision and called for intervention by the White House.

Some of Makary and Prasad’s most controversial vaccine proposals never came to fruition, despite stoking confusion and anxiety within the FDA and beyond.

In an internal memo in November, Prasad claimed — without publishing evidence — that the FDA had linked COVID-19 shots to the deaths of 10 children. Prasad used that to justify a planned overhaul of the agency’s approach to approving vaccines.

A dozen former FDA commissioners issued a scathing denunciation of the planwarning it would “undermine the public interest” and decimate vaccine development. The FDA has not released its analysis of the deaths or its plan for the vaccine overhaul.

FDA’s drug center had a revolving door

In the FDA’s drug center, which is the agency’s largest division, Makary oversaw a revolving door of leadership changes. Six people served as director over the course of one year.

Makary’s initial pick for the job, Dr. George Tidmarsh, was forced to resign after allegations that he used his FDA position to pursue a personal vendetta against a former business partner.

His replacement, longtime FDA cancer specialist Dr. Rick Pazdurannounced he would retire after just three weeks on the job, after clashing with Makary on multiple issues surrounding drug reviews.

With Makary’s departure, the fate of many of his fledgling initiatives is uncertain.

Most of the programs Makary introduced have not gone through federal rulemaking required to enshrine them in U.S. law. Democrats in Congress have questioned the legality of some of those efforts, including a program that offers drugmakers expedited reviews for innovative medicines.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.